In October 2025, I spent three days in Boston at the Biomarkers of Aging Conference, a meeting that brings together the sharpest thinkers in the fields of aging research. In this post, I’ve distilled five key takeaways: from why the most promising window to slow biological aging sits between 30 and 49 to showing the gap between technical precision and biological stability in epigenetic clocks.
1. The window to slow biological aging lies between 30 and 49
Terrie Moffitt, Associate Director of the Dunedin Longitudinal Study longitudinal cohort, showed that the most effective window to slow the biological pace of aging lies between 30 and 49 years, before critical accumulation of damage. This period represents a “plastic” phase when biological systems can still recalibrate, making it the ideal age range for testing rejuvenation therapies in clinical studies.
2. GLP-1 agonists slow down aging
Adding translational context, Varun Dwaraka and collaborators reported the first randomized trial demonstrating that the GLP-1 agonist semaglutide significantly slowed epigenetic aging. Over 32 weeks, participants showed a 3-year reduction and a ≈ 9 % slower pace of aging. These findings suggest that metabolic drugs can directly modulate DNA-methylation trajectories, linking energy regulation with cellular rejuvenation.
So far, all of this work has been done in the blood. We remain extremely curious how these results would look in the skin!
3. Epigenetic clock technical precision ≠ biological stability
Researchers Raghav Sehgal and Albert Higgins-Chen from Yale University benchmarked 18 epigenetic clocks and showed that while most reach excellent technical reproducibility (intraclass correlation coefficient > 0.9 across arrays and replicates), biological reliability, the stability of results across meals, stress, or pollution, remains modest. Even high-performing clocks such as GrimAge V2 or DunedinPACE can fluctuate by several “biological years” within a day.
4. Epigenetic aging happens in networks, not isolated sites
Wolfgang Wagner, Director of the Institute for Stem Cell Biology at Aachen University, showed that targeted methylation editing at age-associated CpGs triggers genome-wide bystander effects, coordinated changes across distant loci, revealing that clocks operate within an interconnected epigenetic aging network, not as isolated sites.
5. The skin’s unique methylation pattern
One of the most thought-provoking talks came from Macsue Jacques from Monash University, who presented the Methylation Atlas: a panoramic view of how aging reshapes the human methylome across tissues.
Among tissues, skin stood out. It carries nearly 19k age-related methylation changes (differentially methylated positions) but only ~1.2 k variable sites (variably methylated positions), meaning most aging signals are directional and reproducible, not random drift.
Over 80 % of these CpGs fall within low- or intermediate-methylation states (< 75 %), the genome’s “regulatory sweet spots.” Aging in skin follows a consistent dual pattern:
- Hypermethylation of chromatin-regulatory genes (tighter nuclear control)
- Hypomethylation of metabolic pathways (weakened energy balance)
Together, these reflect the nuclear–cytoplasmic imbalance seen across aging tissues.
Mitra Bio: taking these insights to skin aging trials
The insights from this conference inform and corroborate the skin aging research that we’ve been doing at Mitra Bio.
First, we must identify and track rejuvenation within the optimal biological window. By targeting the 30–49-year intervention window, we can quantify how treatments truly slow or reverse epidermal aging, using our non-invasive skin methylome profiling, before structural decline sets in.
Secondly, our skin-specific clocks prioritise CpGs in regions with strong directional consistency but low short-term volatility, ensuring both reproducibility and stability.
Finally, the Methylation Atlas findings clarify why our skin-specific clocks rely heavily on hypomethylated CpGs: they’re not just technically stable, but biologically enriched for true age-related change. The Atlas provides the mechanistic rationale behind that design choice.
Mitra Bio has developed a non-invasive skin diagnostics platform that measures biological skin aging. Since skin aging is a highly visible biomarker, tackling it could significantly advance the field of longevity.
If you’re developing longevity ingredients and want to track efficacy using DNA methylation age clocks, let’s connect.
References
- Corley MJ, Dwaraka V, Pang AP, et al. MedRxiv Preprint. 2025 Jul 14:2025.07.09.25331038.
- Sehgal R, Borrus D, Gonzalez J, et al. BioRxiv Preprint. 2025 Oct 14. DOI: https://doi.org/10.1101/2025.10.13.682176
- Liesenfelder S, Mabrouk MHE, Iliescu J, et al. Nature Aging. 2025 Jun;5(6):997-1009.
- Jacques M, Seale K, Voisin S, et al. BioRxiv Preprint. 2025 Jul 24. DOI: https://doi.org/10.1101/2025.07.21.665830
